Halo Biosciences
Modulating the extracelluar matrix (ECM) to transform inflammatory and fibrotic diseases
Halo Biosciences
Modulating the extracelluar matrix (ECM) to transform inflammatory and fibrotic diseases
Our Mission
Halo is a clinical-stage biotechnology company with a mission to create first-in-class, disease-modifying therapies for the treatment of inflammatory and fibrotic diseases. Our first indication is pulmonary hypertension and interstitial lung disease.
Our Science
The ECM in Disease
Our approach centers on reducing pathologic accumulation of hyaluronan (HA), a key structural and signaling component of the ECM, to mitigate downstream inflammatory and metabolic dysfunction.
Dysregulated HA is implicated in chronic inflammation and fibrosis across multiple indications, including pulmonary hypertension, pulmonary fibrosis, and liver fibrosis.
Utilizing cutting-edge advances in research and development, our goal is to leverage our research on 4-methylumbelliferone (4-MU) to suppress inflammatory responses, restore healthier tissue metabolism, and deliver safe, effective medicines for patients.
Our Pipeline
Novel target for pulmonary hypertension
Our lead pipeline candidate, H1614, is a reformulation of 4-methylumbelliferone, with the potential to be a first- and best-in-class hyaluronan (HA) remodeling agent for the treatment of patients with Group 3 pulmonary hypertension.
Preclinical and clinical data suggest that targeting the HA pathway can address the inflammation, fibrosis, and vascular remodeling associated with disease progression.